These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 23774432

  • 1. Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine.
    Jones SA, Murakami E, Delaney W, Furman P, Hu J.
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4181-9. PubMed ID: 23774432
    [Abstract] [Full Text] [Related]

  • 2. Hepatitis B virus reverse transcriptase - Target of current antiviral therapy and future drug development.
    Clark DN, Hu J.
    Antiviral Res; 2015 Nov; 123():132-7. PubMed ID: 26408354
    [Abstract] [Full Text] [Related]

  • 3. Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations.
    Nakajima S, Watashi K, Kato T, Muramatsu M, Wakita T, Tamura N, Hattori SI, Maeda K, Mitsuya H, Yasutake Y, Toyoda T.
    J Virol; 2021 Jul 26; 95(16):e0240120. PubMed ID: 34076480
    [Abstract] [Full Text] [Related]

  • 4. Priming of duck hepatitis B virus reverse transcription in vitro: premature termination of primer DNA induced by the 5'-triphosphate of fialuridine.
    Staschke KA, Colacino JM.
    J Virol; 1994 Dec 26; 68(12):8265-9. PubMed ID: 7525986
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
    Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, Arnold E.
    J Virol; 2001 May 26; 75(10):4771-9. PubMed ID: 11312349
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of reverse transcriptase activity of hepatitis B virus polymerase by β-l-D4A-TP.
    Wang XY, Gao LL, Hu ZH, Wang HL, Deng F, Jin JS.
    Acta Virol; 2008 May 26; 52(1):47-52. PubMed ID: 18459835
    [Abstract] [Full Text] [Related]

  • 9. Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir.
    Walsh AW, Langley DR, Colonno RJ, Tenney DJ.
    PLoS One; 2010 Feb 12; 5(2):e9195. PubMed ID: 20169198
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Reverse transcriptase activity of hepatitis B virus (HBV) DNA polymerase within core capsid: interaction with deoxynucleoside triphosphates and anti-HBV L-deoxynucleoside analog triphosphates.
    Lam W, Li Y, Liou JY, Dutschman GE, Cheng YC.
    Mol Pharmacol; 2004 Feb 12; 65(2):400-6. PubMed ID: 14742682
    [Abstract] [Full Text] [Related]

  • 12. Modeling the functional state of the reverse transcriptase of hepatitis B virus and its application to probing drug-protein interaction.
    Xu X, Thai H, Kitrinos KM, Xia G, Gaggar A, Paulson M, Ganova-Raeva L, Khudyakov Y, Lara J.
    BMC Bioinformatics; 2016 Aug 31; 17 Suppl 8(Suppl 8):280. PubMed ID: 27587008
    [Abstract] [Full Text] [Related]

  • 13. Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance.
    Menéndez-Arias L, Álvarez M, Pacheco B.
    Curr Opin Virol; 2014 Oct 31; 8():1-9. PubMed ID: 24814823
    [Abstract] [Full Text] [Related]

  • 14. Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients.
    Kwon SY, Park YK, Ahn SH, Cho ES, Choe WH, Lee CH, Kim BK, Ko SY, Choi HS, Park ES, Shin GC, Kim KH.
    J Virol; 2010 May 31; 84(9):4494-503. PubMed ID: 20164224
    [Abstract] [Full Text] [Related]

  • 15. Mechanism of Adefovir, Tenofovir and Entecavir Resistance: Molecular Modeling Studies of How A Novel Anti-HBV Agent (FMCA) Can Overcome the Drug Resistance.
    Rawal RK, Konreddy AK, Chu CK.
    Curr Med Chem; 2015 May 31; 22(34):3922-32. PubMed ID: 26336997
    [Abstract] [Full Text] [Related]

  • 16. Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery.
    Rhee SY, Margeridon-Thermet S, Nguyen MH, Liu TF, Kagan RM, Beggel B, Verheyen J, Kaiser R, Shafer RW.
    Antiviral Res; 2010 Dec 31; 88(3):269-75. PubMed ID: 20875460
    [Abstract] [Full Text] [Related]

  • 17. Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.
    Yasutake Y, Hattori SI, Tamura N, Matsuda K, Kohgo S, Maeda K, Mitsuya H.
    Sci Rep; 2020 Feb 20; 10(1):3021. PubMed ID: 32080249
    [Abstract] [Full Text] [Related]

  • 18. Non-nucleoside hepatitis B virus polymerase inhibitors identified by an in vitro polymerase elongation assay.
    Nakajima S, Watashi K, Fukano K, Tsukuda S, Wakae K, Aizaki H, Muramatsu M, Wakita T, Toyoda T.
    J Gastroenterol; 2020 Apr 20; 55(4):441-452. PubMed ID: 31768802
    [Abstract] [Full Text] [Related]

  • 19. Understanding the unique mechanism of L-FMAU (clevudine) against hepatitis B virus: molecular dynamics studies.
    Chong Y, Chu CK.
    Bioorg Med Chem Lett; 2002 Dec 02; 12(23):3459-62. PubMed ID: 12419383
    [Abstract] [Full Text] [Related]

  • 20. Differential binding of tenofovir and adefovir to reverse transcriptase of hepatitis B virus.
    van Hemert FJ, Berkhout B, Zaaijer HL.
    PLoS One; 2014 Dec 02; 9(9):e106324. PubMed ID: 25180507
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.